SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after its "monster beat" earnings report, which highlighted strong revenue growth and raised FY2026 guidance to $40 billion, driving community discussions around significant undervaluation and short squeeze potential despite critical analyst ratings.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after reporting strong Q4 earnings that surpassed estimates, yet its Q1 revenue guidance, perceived as softer than elevated AI expectations, triggered a 'sell the news' reaction. The community is actively debating if the market's swift correction is an overreaction to otherwise robust long-term data center growth projections and confirmed product timelines.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing a significant sell-off after unexpected 2026 guidance projected declining sales, fueling widespread community frustration with management's pessimistic tone. Investors are actively debating the impact of fierce GLP-1 competition and US pricing pressures, despite promising early demand for its oral weight-loss pill.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending after its Q4 earnings report presented a mixed picture, showing strong revenue growth and record free cash flow but missing adjusted EPS estimates and providing a slightly softer Q1 outlook. The community is actively debating whether the company's robust platform growth and long-term autonomous vehicle strategy as an aggregator can overcome immediate profit concerns and increasing competition.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to a strong Q4 earnings beat and an optimistic 2026 outlook, fueled by explosive demand for its GLP-1 drugs Mounjaro and Zepbound, which further establishes its market leadership over rivals, despite community discussions around its high valuation and calls for a stock split.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending after reporting strong earnings and an optimistic outlook, prompting multiple analyst upgrades and widespread community discussion about a potential solar sector recovery and a short squeeze, bolstered by new product introductions.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings Inc. is seeing significant momentum following a substantial earnings beat and robust forward guidance, propelled by surging demand for its optical components essential to AI and cloud infrastructure. The community is actively discussing massive analyst price target upgrades and the company's pivotal role in the AI buildout, even as some debate its rapidly expanding valuation.

Silicon Laboratories, Inc. engages in providing and developing analog-intensive and mixed-signal integrated circuits. It focuses on wireless development platform and product portfolio for the internet of things based on Bluetooth, sub-GHz proprietary technologies, Wi-SUN, Thread, Wi-Fi, Zigbee, and Z-Wave. The company was founded by Navdeep S. Sooch, David R. Welland, and Jeffrey W. Scott in August 1996 and is headquartered in Austin, TX.

Silicon Laboratories Inc

Silicon Labs is trending following a definitive agreement for Texas Instruments to acquire the company for $231 per share in an all-cash transaction. The community is actively discussing the significant premium and the market's reaction, viewing it as another instance of semiconductor industry consolidation driven by strong demand for specialized IoT and wireless solutions.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending following strong Q4 earnings, driven by robust immunology and neuroscience growth that supported raised 2026 EPS guidance. The community is actively discussing the company's strategic moves, including a significant cancer licensing deal and a large domestic investment pledge, alongside ongoing speculation about broader M&A and industry pricing dynamics.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is actively discussed after beating Q4 earnings expectations across revenue and adjusted EPS, though the stock is experiencing a pullback driven by a softer 2026 sales growth outlook and short-term earnings dilution concerns related to the Penumbra acquisition, which many in the community view as strengthening the long-term bull case.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) EVP Sells 26,269 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) EVP Zachary Roberts sold 26,269 shares of the company's stock in a transaction dated Wednesday, January 21st. The stock was sold at an...

Are Medical Stocks Lagging  Allogene Therapeutics (ALLO) This Year?

Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.

Allogene Therapeutics (NASDAQ:ALLO) Trading 4.4% Higher - Here's Why

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 4.4% - What's Next...

Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors

Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors There are just nine days left in the year, and this year has flown by. We've delivered readers a steady stream of 2026...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat...

Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen

Wall Street Zen raised Allogene Therapeutics from a "sell" rating to a "hold" rating in a report on Friday...

Foresite Capital Management VI LLC Sells 572,918 Shares of Allogene Therapeutics, Inc. $ALLO

Foresite Capital Management VI LLC decreased its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 16.6% in the 2nd quarter, according to its most recent 13F filing...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twelve research firms that are presently covering the firm, MarketBeat...

HC Wainwright Has Strong Estimate for ALLO FY2025 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a report released on Monday...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Allogene Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $GOOGL earnings on Wednesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.23	--	--	N/A
Q3 '25	-$0.22	-$0.19	13.95%	BEAT
Q2 '25	-$0.27	-$0.23	14.07%	BEAT
Q1 '25	-$0.29	-$0.28	3.60%	BEAT
Q4 '24	-$0.33	-$0.28	14.25%	BEAT

ALLO
Allogene Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ALLO News

ALLOAllogene Therapeutics Inc